

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	The Hydration Pharmaceuticals Company Limited
ACN	620 385 677

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Adem Karafili
Date of last notice	4 October 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Ankara Holdings Pty Ltd <The Ankara Family Trust>* (Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.)
Date of change	2 September 2024
No. of securities held prior to change Ankara Holdings Pty Ltd <The Ankara Family Trust>*	2,562,389 fully paid ordinary shares 74,739 unlisted options with an exercise price of \$0.4482 expiring on 13 January 2029 500,000 unlisted options exercisable at \$0.07 per option and expiring on 31 December 2025. 100,000 unlisted options with an exercise price of \$0.29 expiring on 31 August 2024 800,000 unlisted options with an exercise price of \$0.20 expiring on 31 August 2024

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

<p>Ankara Holdings Pty Ltd ATF A&N Karafili Family Trust*</p> <p>*Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.</p>	<p>1,000,000 unlisted options with an exercise price of \$0.2882 expiring on 1 December 2026</p> <p>53,571 unlisted options issued under the EIP exercisable at \$0.4742 per option and expiring on 22 July 2027</p>
Class	Unlisted Options
Number acquired	Nil
Number disposed	900,000 unlisted options
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	N/A
No. of securities held after change <p>Ankara Holdings Pty Ltd <The Ankara Family Trust>*</p> <p>2,562,389 fully paid ordinary shares</p> <p>74,739 unlisted options with an exercise price of \$0.4482 expiring on 13 January 2029</p> <p>500,000 unlisted options exercisable at \$0.07 per option and expiring on 31 December 2025.</p> <p>1,000,000 unlisted options with an exercise price of \$0.2882 expiring on 1 December 2026.</p> <p>Ankara Holdings Pty Ltd ATF A&N Karafili Family Trust*</p> <p>53,571 unlisted options issued under the EIP exercisable at \$0.4742 per option and expiring on 22 July 2027</p> <p>*Adem Karafili has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities.</p>	
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Cancellation of unlisted options due to expiry.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

+ See chapter 19 for defined terms.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.